AIMS/HYPOTHESIS: Type 1 diabetes is associated with a higher risk of major vascular complications and death. A reliable method that predicted these outcomes early in the disease process would help in risk classification. We therefore developed such a prognostic model and quantified its performance in independent cohorts. METHODS: Data were analysed from 1,973 participants with type 1 diabetes followed for 7 years in the EURODIAB Prospective Complications Study. Strong prognostic factors for major outcomes were combined in a Weibull regression model. The performance of the model was tested in three different prospective cohorts: the Pittsburgh Epidemiology of Diabetes Complications study (EDC, n = 554), the Finnish Diabetic Nephropathy study (FinnDiane, n = 2,999) and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI, n = 580). Major outcomes included major CHD, stroke, end-stage renal failure, amputations, blindness and all-cause death. RESULTS: A total of 95 EURODIAB patients with type 1 diabetes developed major outcomes during follow-up. Prognostic factors were age, HbA1c, WHR, albumin/creatinine ratio and HDL-cholesterol level. The discriminative ability of the model was adequate, with a concordance statistic (C-statistic) of 0.74. Discrimination was similar or even better in the independent cohorts, the C-statistics being: EDC, 0.79; FinnDiane, 0.82; and CACTI, 0.73. CONCLUSIONS/ INTERPRETATION: Our prognostic model, which uses easily accessible clinical features can discriminate between type 1 diabetes patients who have a good or a poor prognosis. Such a prognostic model may be helpful in clinical practice and for risk stratification in clinical trials.
AIMS/HYPOTHESIS: Type 1 diabetes is associated with a higher risk of major vascular complications and death. A reliable method that predicted these outcomes early in the disease process would help in risk classification. We therefore developed such a prognostic model and quantified its performance in independent cohorts. METHODS: Data were analysed from 1,973 participants with type 1 diabetes followed for 7 years in the EURODIAB Prospective Complications Study. Strong prognostic factors for major outcomes were combined in a Weibull regression model. The performance of the model was tested in three different prospective cohorts: the Pittsburgh Epidemiology of Diabetes Complications study (EDC, n = 554), the Finnish Diabetic Nephropathy study (FinnDiane, n = 2,999) and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI, n = 580). Major outcomes included major CHD, stroke, end-stage renal failure, amputations, blindness and all-cause death. RESULTS: A total of 95 EURODIAB patients with type 1 diabetes developed major outcomes during follow-up. Prognostic factors were age, HbA1c, WHR, albumin/creatinine ratio and HDL-cholesterol level. The discriminative ability of the model was adequate, with a concordance statistic (C-statistic) of 0.74. Discrimination was similar or even better in the independent cohorts, the C-statistics being: EDC, 0.79; FinnDiane, 0.82; and CACTI, 0.73. CONCLUSIONS/ INTERPRETATION: Our prognostic model, which uses easily accessible clinical features can discriminate between type 1 diabetespatients who have a good or a poor prognosis. Such a prognostic model may be helpful in clinical practice and for risk stratification in clinical trials.
Authors: R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham Journal: Eur Heart J Date: 2003-06 Impact factor: 29.983
Authors: Dana Dabelea; Gregory Kinney; Janet K Snell-Bergeon; John E Hokanson; Robert H Eckel; James Ehrlich; Satish Garg; Richard F Hamman; Marian Rewers Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: David M Nathan; Bernard Zinman; Patricia A Cleary; Jye-Yu C Backlund; Saul Genuth; Rachel Miller; Trevor J Orchard Journal: Arch Intern Med Date: 2009-07-27
Authors: Juma Alkaabi; Charu Sharma; Javed Yasin; Bachar Afandi; Salem A Beshyah; Raya Almazrouei; Ahmed Alkaabi; Sania Al Hamad; Luai A Ahmed; Rami Beiram; Elhadi H Aburawi Journal: Am J Transl Res Date: 2022-07-15 Impact factor: 3.940
Authors: Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Julia Szendroedi; Aaruni Saxena; Katharina S Weber; Klaus Strassburger; Christian Herder; Volker Burkart; Bettina Nowotny; Andrea Icks; Oliver Kuss; Dan Ziegler; Hadi Al-Hasani; Karsten Müssig; Michael Roden Journal: Cardiovasc Diabetol Date: 2016-04-07 Impact factor: 9.951